Omeros Corporation Stock News

Gregory Demopulos became the CEO of Omeros Corporation (NASDAQ:OMER) in 1994. This report will, first, examine the CEO...

Omeros Corporation (NASDAQ: OMER) today announced the appointment of Kurt Zumwalt, former global treasurer of Amazon.com, Inc., to Omeros’ Board of Directors. He will also serve in a consulting role

Omeros Corporation has had positive news regarding its late-stage candidate OMS721 counterbalanced by concerns that its product Omidria may lose its separate re

Equities research analysts expect Omeros Co. (NASDAQ:OMER) to report ($0.33) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for O

This article presents a list of stocks with the highest short interest as a percentage of shares outstanding. The most heavily shorted stocks here are generally

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 3.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aptose Bioscien

Omeros (NASDAQ:OMER) was downgraded by equities research analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a report issued on Tuesday, BidAskClub reports. Several other

Pomerantz LLP is investigating claims on behalf of investors of Omeros Corporation (“Omeros” or the “Company”) (OMER). Such investors are advised to contact Robert S. Willoughby at rswillough

Monday's morning session saw 187 companies set new 52-week lows. Interesting Highlights: Xperi (NASDAQ: XPER) was the biggest company on a market cap basis to set a...

The new February selections for both Positive and Negative Forensic Value stocks released in alternating months with the Piotroski-Graham Value selections. 11 P

Friday's morning session saw 167 companies set new 52-week lows. Facts of Interest: The largest company in terms of market cap to set a new 52-week low was Xperi (...

Omeros (NASDAQ:OMER) and Johnson & Johnson (NYSE:JNJ) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ow

The "Obsessive-Compulsive Disorder - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Dublin, Jan. 24, 2020 -- The "Obsessive-Compulsive Disorder - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.This.